THE NATIONAL HEALTH SERVICE ACT 2006

The Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2020

The Secretary of State gives the following Directions in exercise of the powers conferred by sections 127, 128, 272(7) and (8) and 273(1) of the National Health Service Act 2006(a).

Citation, commencement, application and interpretation

1.—(1) These Directions may be cited as the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) Directions 2020, and—

(a) apart from directions 2 and 4, come into force immediately after they are signed;

(b) directions 2 and 4 come into force on 1st April 2020.

(2) These Directions apply in relation to England.

(3) In these Directions, “the 2013 Directions” means the Pharmaceutical Services (Advanced and Enhanced Services) (England) Directions 2013(b).

Amendment of direction 5 of the 2013 Directions

2.—(1) Direction 5 of the 2013 Directions(e) (MUR services: ongoing conditions of arrangements) is amended as follows.

(2) In paragraph (1), for sub-paragraph (g) substitute—

“(g) at least 70% of the MUR service consultations carried out by P—

(i) in the period beginning on 1st April 2020 and ending at the end of 30th June 2020, are to be carried out with patients who are in one or both of the national target groups set out in paragraphs 1 and 2 of Schedule 1, and

(a) 2006 c. 41. Section 127 has been amended by the Health and Social Care Act 2012 (c. 7) ("the 2012 Act"), Schedule 4, paragraph 64; and section 128 has been amended by the 2012 Act, Schedule 4, paragraph 65.


(c) A relevant amendment was made by the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 3) Directions 2019, signed on 11th September 2019.
(ii) in the period beginning on 1st July 2020 and ending at the end of 31st March 2021, are to be carried out with patients who are in the national target group set out in paragraph 1 of Schedule 1;”.

Amendment of direction 14 of the 2013 Directions

3.—(1) Direction 14 of the 2013 Directions(a) (enhanced services provided by pharmacy contractors) is amended as follows.

(2) In paragraph (1), in sub-paragraph (u)—

(a) after “cases of urgency” insert “or whilst a disease is or in anticipation of a disease being imminently pandemic and a serious risk or potentially a serious risk to human health”; and

(b) in paragraph (ii), for from “regulation 225(1)” to “patient’s request)” substitute “regulation 225 or 226 of the Human Medicines Regulations 2012(b) (which relate to emergency sale etc. by pharmacist either at patient’s request or while a disease is or in anticipation of a disease being imminently pandemic and a serious risk or potentially a serious risk to human health)”.


Signed by authority of the Secretary of State for Health and Social Care

Jenine Howe
Head of Pharmacy

Department of Health and Social Care

6th March 2020

(a) A relevant amendment was made by the Pharmaceutical Services (Advanced and Enhanced Services) (England) (Amendment) (No. 2) Directions 2013, signed on 6th December 2013.
(b) S.I. 2012/1916. Regulation 225 has been amended by S.I. 2014/490.